SAN DIEGO and STOCKHOLM, June 4 /PRNewswire/ -- Amgen executive Alan Raffensperger has been appointed the new Chief Executive Officer of BeneChill, a privately held medical device company launching its first product, a novel cooling device for use by emergency response teams in the field, later this year in Europe. With more than 25 years of experience in the pharmaceutical, biotechnology, medical device and diagnostic industries, Mr. Raffensperger joins BeneChill from his post as Executive Director and Franchise Head of Nephrology for Amgen, a global biopharmaceutical company. He joined Amgen in 2005 as General Manager of the Nordic and Baltic Region, overseeing operations in eight countries from his Sweden base.
(Photo: http://photos.prnewswire.com/prnh/20100604/LA15970 )
(Photo: http://www.newscom.com/cgi-bin/prnh/20100604/LA15970 )
"As we prepare to launch our lead RhinoChill™ product in Europe, it was critical that we recruit a seasoned, well-rounded CEO with big pharma experience and the sensitivity to a smaller company," said Denise Barbut, M.D., Executive Chair and founder of BeneChill. "Ala